
There is no demonstrated mortality benefit from digoxin in patients with HFrEF, and elevated levels may increase risk. Digitoxin may reduce hospitalization rates but does not significantly impact mortality.
digitalis, heart function, cardiology, heart failure, patient outcomes, pharmacology, mortality, ejection fraction, low ejection fraction, cardiac glycosides
digitalis, heart function, cardiology, heart failure, patient outcomes, pharmacology, mortality, ejection fraction, low ejection fraction, cardiac glycosides
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
